MarketFriction

Denis Chem Lab Ltd

BSE 537536 · Pharmaceuticals
₹67.41 -0.59%
BSE close2026-10-01
Market cap₹95.2 Cr.
P/E11.9

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales45.4340.0639.8541.2647.8242.8441.3843.2846.1745.5246.7544.00
Expenses40.2934.0734.7736.9141.9439.0139.3238.4641.9139.4944.2140.17
Operating Profit5.145.995.084.355.883.832.064.824.266.032.543.83
OPM %11.31%14.95%12.75%10.54%12.30%8.94%4.98%11.14%9.23%13.25%5.43%8.70%
Other Income0.520.260.590.320.580.301.170.300.650.440.540.45
Interest0.090.130.230.120.090.070.230.190.230.220.200.11
Depreciation1.761.841.751.631.661.841.731.611.651.831.741.53
Profit before tax3.814.283.692.924.712.221.273.323.034.421.142.64
Tax %33.07%25.23%26.02%28.77%25.05%20.72%44.09%25.30%27.06%24.66%64.91%22.73%
Net Profit2.543.202.732.083.531.760.712.482.213.320.402.05
EPS in Rs1.832.311.971.502.541.270.511.791.592.390.291.48
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales98112107123135109136161167173181182
Expenses89989511012099122142146157164166
Operating Profit81412141510141921161817
OPM %9%12%11%11%11%9%11%12%13%9%10%9%
Other Income011200111222
Interest765332111111
Depreciation676676687777
Profit before tax-32266391115111211
Tax %30%37%-5%-7%26%27%30%28%26%27%29%
Net Profit-4126426811888
EPS in Rs-4.160.891.544.583.031.634.515.668.045.826.065.75
Dividend Payout %0%0%0%22%0%46%33%35%31%26%41%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth6%11%4%4%
Compounded Profit Growth15%30%2%-6%
Stock Price CAGR-2%1%-14%-26%
Return on Equity9%11%11%10%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital9912141414141414141414
Reserves8718364345485358667178
Borrowings484437252314932114
Other Liabilities172427262625222725282629
Total Liabilities81859410110697929699109112125
Fixed Assets424044405046414235383937
CWIP0101500002000
Investments000000000000
Other Assets393549565552515562727388
Total Assets81859410110697929699109112125
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity14217118138171618124
Cash from Investing Activity-28-13-1-16-2-2-1-10-11-15-8-5
Cash from Financing Activity13-7-01-5-14-6-7-4-4-40
Net Cash Flow-115-41-31-01-1-0-0
Free Cash Flow-14852-21161212114-1
CFO/OP154%246%49%92%65%101%85%126%100%104%105%38%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days12385104105106941108571696578
Inventory Days403935525051605039433740
Days Payable811191361501021081039979908181
Cash Conversion Cycle814385537673631222136
Working Capital Days-19-57-1341732635141373850
ROCE %11%5%12%9%11%11%6%14%16%20%14%14%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters38.98%38.98%38.98%38.98%38.98%38.98%38.98%38.98%38.98%38.98%38.98%38.98%
FIIs0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.01%0.01%0.01%0.01%0.01%
Public61.02%61.02%61.01%61.02%61.01%61.01%61.02%61.01%61.00%61.00%61.01%61.01%
No. of Shareholders4,6354,7944,8346,0216,8577,3857,2187,2277,3047,1026,9276,811

Fundamentals

Market Cap₹ 95.2 Cr.
Current Price₹ 68.6
Stock P/E11.9
Book Value₹ 66.0
ROCE14.0 %
ROE9.52 %
Dividend Yield3.64 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)4%
Compounded Profit Growth (TTM)-6%
Standalone figures.
Valuation
Market capRs 94 Cr
Enterprise valueRs 69 Cr
P/E (TTM)11.72x
Price to book1.02x
Price to sales0.51x
EV / EBITDA3.67x
EV / EBIT5.73x
EV / sales0.38x
Price to cash flow22.65x
Earnings yield8.53%
Dividend yield3.71%
P/E, 3-year average14.67x
P/B, 3-year average1.66x
P/E, 5-year average14.07x
P/B, 5-year average1.52x
Profitability
Operating margin (excl. other income)9.73%
Operating margin (incl. other income)10.78%
EBITDA margin10.27%
Pre-tax margin6.16%
Net profit margin4.37%
Net margin, latest quarter4.66%
ROE9.52%
ROCE14.01%
ROA7.09%
ROE, 3-year average11.30%
ROCE, 3-year average16.01%
ROA, 3-year average8.36%
ROE, 5-year average11.00%
ROCE, 5-year average15.58%
ROA, 5-year average7.95%
ROIC (approx.)12.70%
Tax rate29.27%
Other income / net worth2.10%
Growth
Sales growth (latest year)4.79%
Profit growth (latest year)4.08%
Sales CAGR, 3 years4.16%
Sales CAGR, 5 years10.78%
Profit CAGR, 3 years2.28%
Profit CAGR, 5 years30.06%
Sales growth QoQ-5.88%
Profit growth QoQ412.50%
Sales growth YoY (latest quarter)1.66%
Profit growth YoY (latest quarter)-17.34%
Per share
EPS (TTM)Rs 5.75
EPS (latest year)Rs 6.06
EPS (latest quarter)Rs 1.48
EPS, 3-year averageRs 6.64
EPS, 5-year averageRs 6.02
Book value per shareRs 66.00
Sales per shareRs 131.47
Cash flow per shareRs 2.98
Free cash flow per shareRs -0.72
Dividend per share (latest year)Rs 2.50
Dividend per share, 3-year averageRs 2.17
Dividend per share, 5-year averageRs 2.00
Dividends
Dividend payout41.26%
Dividend payout, 3-year average32.70%
Dividend payout, 5-year average33.34%
Efficiency
Asset turnover1.45x
Fixed asset turnover4.89x
Inventory turnover10.59x
Inventory days34 days
Debtor days78 days
Debtors turnover4.70x
Creditor days81 days
Cash conversion cycle36 days
Working capital days50 days
Leverage
Total debtRs 4 Cr
Cash and bankRs 29 Cr
Net debtRs -25 Cr
Debt to equity0.05x
Net debt / EBITDA-1.32x
Interest coverage15.78x
Owners' fund to total sources73.37%
Debt to assets3.35%
Cash flow
Cash from Operating Activity (latest year)Rs 4 Cr
Cash from Investing Activity (latest year)Rs -5 Cr
Cash from Financing Activity (latest year)Rs 0 Cr
Net Cash Flow (latest year)Rs -0 Cr
Free cash flow (latest year)Rs -1 Cr
FCFE (approx.: FCF + change in debt)Rs 2 Cr
Cash from ops / profit, 5 years1.63x
Sales to cash flow43.94x
Statement figures
Net sales (TTM)Rs 182 Cr
Net sales (latest year)Rs 181 Cr
Sales (latest quarter)Rs 44 Cr
Operating profit excl. other income (latest year)Rs 18 Cr
Operating profit (latest quarter)Rs 4 Cr
Other income (TTM)Rs 2 Cr
EBITDA (TTM)Rs 19 Cr
PBDT (TTM)Rs 18 Cr
Profit before tax (TTM)Rs 11 Cr
Tax (latest year)Rs 3 Cr
Net profit (TTM)Rs 8 Cr
Net profit (latest year)Rs 8 Cr
Net profit (latest quarter)Rs 2 Cr
Depreciation (TTM)Rs 7 Cr
Depreciation (latest quarter)Rs 2 Cr
Interest (TTM)Rs 1 Cr
Cost of goods sold (latest year)Rs 112 Cr
Total expenditure (latest year)Rs 164 Cr
Total income (latest year)Rs 183 Cr
Share capitalRs 14 Cr
ReservesRs 78 Cr
Shareholders' fundsRs 92 Cr
Total assetsRs 125 Cr
Net blockRs 37 Cr
ReceivablesRs 39 Cr
InventoryRs 11 Cr
Other liabilitiesRs 29 Cr
Shares outstanding (crore)1.39
Ownership
Promoter holding38.98% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 11.7 is at the 13th percentile of its own 9.4-year range (median 18.3, low 5.6, high 141.1).
P/B 1.02 is at the 15th percentile (median 1.59).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
Period537536Nifty 50Difference
1 week-2.5%-2.8% +0.3 pts
1 month-7.4%-6.8% -0.6 pts
3 months-9.9%-7.6% -2.3 pts
3 years-37.6%+14.2% -51.7 pts
5 years+2.4%+27.9% -25.4 pts

Red flags

F-score 4 of 8
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹44 Cr +1.7% vs Jun 2025. Net profit ₹2 Cr -17.3%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Denis Chem Lab Ltd?

Denis Chem Lab Ltd (537536) has a market capitalisation of Rs 95.2 Cr. at the 2026-10-01 close.

What is the P/E ratio of Denis Chem Lab Ltd?

Denis Chem Lab Ltd trades at a P/E of 11.9 on trailing twelve-month profit, at the 2026-10-01 close.

What were Denis Chem Lab Ltd's latest quarterly results?

In the Jun 2026 quarter, Denis Chem Lab Ltd sales was Rs 44 Cr (+1.7% vs Jun 2025) and net profit was Rs 2 Cr.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03